The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep apnea (OSA). The present study is a Phase 3 open label continuation protocol enrolling qualifying participants who completed one of the parent Phase 3 double-blind placebo-controlled studies, APC-APN-304 or APC-APN-305.

开始日期2024-07-03

申办/合作机构

Apnimed, Inc.

NCT06400615

/ Completed临床2期

Phase 2 Safety, Efficacy and, Tolerability of Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) in Obstructive Sleep Apnea Patients Taking Tirzepatide, Semaglutide or Liraglutide

开始日期2024-05-20

申办/合作机构

Apnimed, Inc.

NCT05813275

/ Completed临床3期

Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) to Placebo in Obstructive Sleep Apnea (SynAIRgy Study)

This is a Phase 3 Randomized Double-Blind Placebo-Controlled 6-month Parallel-Arm Study to Compare a Fixed Dose Combination of AD109 to Placebo in Obstructive Sleep Apnea.

开始日期2023-09-16

申办/合作机构

Apnimed, Inc.

100 项与 Aroxybutynin/Atomoxetine 相关的临床结果

登录后查看更多信息

100 项与 Aroxybutynin/Atomoxetine 相关的转化医学

登录后查看更多信息

100 项与 Aroxybutynin/Atomoxetine 相关的专利（医药）

登录后查看更多信息

项与 Aroxybutynin/Atomoxetine 相关的文献（医药）

2025-10-01·Contemporary Clinical Trials Communications

Aroxybutynin and atomoxetine (AD109) for the treatment of obstructive sleep apnea: Rationale, design and baseline characteristics of the phase 3 clinical trials

Article

作者: Strollo, Patrick J ; Werner, Andrea ; Taranto-Montemurro, Luigi ; Farkas, Ron ; Cronin, John ; Patel, Sanjay R ; Pho, Huy ; Yee, John

Introduction:

Two key factors leading to obstructive sleep apnea (OSA) pathogenesis include relaxation of upper airway muscles at sleep onset and their insufficient reactivation during obstructive events. Medications that address this neuromuscular dysfunction by increasing upper airway tone during sleep represent a potential strategy for mitigating OSA.

Methods:

AD109 is an investigational, once-daily oral agent taken at bedtime that combines an antimuscarinic, aroxybutynin (2.5 mg), with a selective norepinephrine reuptake inhibitor, atomoxetine (75 mg). LunAIRo (NCT05811247) and SynAIRgy (NCT05813275) are two ongoing, placebo-controlled 51-week and 26-week phase 3 clinical trials, respectively, investigating the efficacy and safety of AD109 to treat mild to severe OSA. Participants include adults with an apnea-hypopnea index with 4% desaturation (AHI₄) >5 who either refuse or fail to tolerate positive airway pressure. Participants (LunAIRo: N = 660; SynAIRgy: N = 646) were randomized 1:1 to receive AD109 or placebo. We hypothesize that AD109 will significantly reduce AHI₄ and symptomatic fatigue compared to placebo in people with OSA. The primary outcome for both trials is the change from baseline to Week 26 in AHI₄ in the AD109 arm versus placebo. Key secondary outcomes include changes from baseline in oxygen desaturation index with 3% desaturation, hypoxic burden based on 4% desaturation, Patient Reported Outcome Measurement Information System (PROMIS)-Fatigue, and proportion of participants with ≥50% reduction in AHI₄ at Week 26.

Discussion:

LunAIRo and SynAIRgy are fully enrolled, large Phase 3 clinical trials designed to confirm and extend our understanding of the safety and efficacy of AD109, a combination oral drug targeting the underlying neuromuscular dysfunction contributing to upper airway muscle collapse during sleep in adults with OSA.

2023-12-15·American journal of respiratory and critical care medicine

The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial

Article

作者: Corser, Bruce ; Ojile, Joseph M. ; Taranto-Montemurro, Luigi ; Maynard, James ; Drake, Christopher L. ; Rosenberg, Russell ; Schweitzer, Paula K. ; Thein, Stephen G. ; Abaluck, Brian ; Sangal, R. Bart

Abstract:

Rationale:

Obstructive sleep apnea (OSA) is a common sleep disorder for which the principal treatment option, continuous positive airway pressure, is often poorly tolerated. There is currently no approved pharmacotherapy for OSA. However, recent studies have demonstrated improvement in OSA with combined antimuscarinic and noradrenergic drugs.

Objectives:

The aim of this study was to evaluate the efficacy and safety of AD109, a combination of the novel antimuscarinic agent aroxybutynin and the norepinephrine reuptake inhibitor atomoxetine, in the treatment of OSA.

Methods:

Phase II randomized, double-blind, placebo-controlled, parallel-group, 4-week trial comparing AD109 2.5/75 mg, AD109 5/75 mg, atomoxetine 75 mg alone, and placebo (www.clinicaltrials.gov identifier NCT 05071612).

Measurements and Main Results:

Of 211 randomized patients, 181 were included in the prespecified efficacy analyses. Sleep was assessed by two baseline and two treatment polysomnograms. Apnea–hypopnea index with a 4% desaturation criterion (primary outcome) was reduced from a median (IQR) of 20.5 (12.3–27.2) to 10.8 (5.6–18.5) in the AD109 2.5/75 mg arm (−47.1%), from 19.4 (13.7–26.4) to 9.5 (6.1–19.3) in the AD109 5/75 mg arm (−42.9%; both P < 0.0001 vs. placebo), and from 19.0 (11.8–28.8) to 11.8 (5.5–21.5) with atomoxetine alone (−38.8%; P < 0.01 vs. placebo). Apnea–hypopnea index with a 4% desaturation criterion decreased from 20.1 (11.9–25.9) to 16.3 (11.1–28.9) in the placebo arm. Subjectively, there was improvement in fatigue with AD109 2.5/75 mg (P < 0.05 vs. placebo and atomoxetine). Atomoxetine taken alone decreased total sleep time (P < 0.05 vs. AD109 and placebo). The most common adverse events were dry mouth, insomnia, and urinary hesitancy.

Conclusions:

AD109 showed clinically meaningful improvement in OSA, suggesting that further development of the compound is warranted.Clinical trial registered with www.clinicaltrials.gov (NCT 05071612).

2022-12-01·Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine

Combination of atomoxetine with the novel antimuscarinic aroxybutynin improves mild to moderate OSA

Article

作者: Thein, Stephen ; Abaluck, Brian ; Rosenberg, Russell

STUDY OBJECTIVE:

Obstructive sleep apnea is a common and serious sleep disorder for which treatment remains challenging due to lack of adherence to approved therapies. Previous pharmacological studies addressing sleep-related upper airway muscle hypotonia suggested that the combination of atomoxetine and oxybutynin is effective in treating obstructive sleep apnea. The current study is with aroxybutynin (AD109), a new enantiomerically pure form of oxybutynin with better safety profile compared to racemic oxybutynin.

METHODS:

This was a randomized, double-blind, placebo-controlled, crossover study in patients with mild to moderate obstructive sleep apnea. Each received low-dose AD109 (37.5/2.5 mg), high-dose AD109 (75/2.5 mg), and placebo at bedtime across 3 overnight periods in a randomized order. Adverse events were collected by telephone contact with participants during each washout period. The primary endpoint was change in hypoxic burden and secondary endpoint was apnea-hypopnea index.

RESULTS:

Patients treated with both the high and low doses of AD109 had a statistically significant and clinically meaningful difference from placebo in hypoxic burden. Median [interquartile range] hypoxic burden for participants on placebo was 13.9[4.5-21.9] (%min)/h vs 2.3[0.1-10.5] (%min)/h for patients on the high dose (P < .001) and to 7.3[2-12.5] (%min)/h on the low dose (P < .01). Apnea-hypopnea index went from a median of 13.2[8.0-19.1] events/h on placebo reduced to 5.5[2.2 to 9.6] events/h on the high dose (P < .001) and to 7.8[4-13.7] events/h on the low dose (P < .05). AD109 demonstrated a favorable safety profile.

CONCLUSIONS:

This study provides additional support that a pharmacological intervention for obstructive sleep apnea, namely the combination of atomoxetine and aroxybutynin, offers promising results. Additional development of this compound and others is warranted.

CLINICAL TRIAL REGISTRATION:

Registry: ClinicalTrials.gov; Name: AD109 Dose Finding in Mild to Moderate OSA; URL: https://clinicaltrials.gov/ct2/show/NCT04631107; Identifier: NCT04631107.

CITATION:

Rosenberg R, Abaluck B, Thein S. Combination of atomoxetine with the novel antimuscarinic aroxybutynin improves mild to moderate OSA. J Clin Sleep Med. 2022;18(12):2837-2844.

项与 Aroxybutynin/Atomoxetine 相关的新闻（医药）

2026-05-11

·BioSpace

Apnimed Announces Three Oral Presentations and a Late-breaking Poster at the American Thoracic Society (ATS) 2026 International Conference

CAMBRIDGE, Mass. , May 11, 2026 /PRNewswire/ -- Apnimed, Inc., a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced multiple presentations, including three oral presentations and a late-breaking poster presentation at the upcoming American Thoracic Society (ATS) 2026 International Conference, which will take place May 15-20, 2026, in Orlando, FL. These presentations will feature a pooled analysis of the SynAIRgy and LunAIRo Phase 3 trials of AD109, Apnimed's lead product candidate, reflecting one of the largest clinical development programs conducted for an obstructive sleep apnea pharmacotherapy, alongside insights into reductions in snoring and estimated cardiovascular risk associated with improvements in hypoxic burden with AD109 treatment. ATS 2026 International Conference Presentation Details: Oral Presentations Title: Aroxybutynin and Atomoxetine (AD109) in Obstructive Sleep Apnea: A Pooled Analysis of the SynAIRgy and LunAIRo Phase 3 Trials Session Type: Scientific Symposium Session Title: A82 Breaking News: Clinical Trial Results in Pulmonary Medicine Session Date, Time: Sunday, May 17, 2026, 2:15-4:15pm EDT Location: Chapin Theater (Level III, OCCC West Concourse) Title: AD109 Significantly Reduces Snoring in Patients with Obstructive Sleep Apnea Session Type: Mini-Symposium Session Title: C21 - From Orexin Agonists to Oxybutynin: A New Era of Pharmacologic Therapies in Sleep Medicine Presentation Date, Time: Tuesday, May 19, 2026, 9:51-10:03am EDT Location: W110A (Level I, OCCC West Concourse) Title: Estimated Reduction in Cardiovascular Risk Associated With Hypoxic Burden Improvement With AD109 in the LunAIRo And SynAIRgy Phase 3 Studies for Obstructive Sleep Apnea Session Type: Mini-Symposium Session Title: C21 - From Orexin Agonists to Oxybutynin: A New Era of Pharmacologic Therapies in Sleep Medicine Session Date, Time: Tuesday, May 19, 2026, 10:15-10:27am EDT Location: W110A (Level I, OCCC West Concourse) Late-breaking Poster Presentation Title: Aroxybutynin and Atomoxetine (AD109) in Obstructive Sleep Apnea: A Pooled Analysis of the SynAIRgy and LunAIRo Phase 3 Trials Poster Board Number: P194 Session Type: Thematic Poster Session Session Title: A79 – Mechanisms, Endotypes, and Physiologic Control in Sleep Apnea Session Date, Time: Sunday, May 17, 11:30am-1:15pm EDT Location: Area A, Halls WA2-WA3 (Level II, OCCC West Concourse) Poster Presentation Title: Deep Learning Optimization of Sleep Stage Classification Using Wearable-Derived SpO2, Pulse Rate, and Movement Features Poster Board Number: 703 Session Title: A30 - Next-Generation Sleep Diagnostics: AI, Wearables, Sensors, and Transformative Technologies Across the Care Continuum Session Date, Time: Sunday, May 17, 2026, 9:15-11:15am EDT Location: W314 (Level III, OCCC West Concourse) About AD109 AD109 is designed to be the first potential pharmacological treatment to improve oxygenation during sleep and target the neuromuscular root cause of upper airway collapse in people with OSA. It is a first-in-class combination of aroxybutynin, a novel antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor (NRI). AD109 is a once-daily pill taken at bedtime that is designed to lower the complexity of intervention and may help more people benefit from effective, restorative sleep. In a disease characterized by complex and invasive treatment options, AD109, if approved, may offer a convenient oral solution to help improve oxygenation and health for people living with OSA. About Obstructive Sleep Apnea OSA is a serious, chronic sleep-related breathing disease in which the upper airway repeatedly collapses during sleep, leading to intermittent oxygen deprivation. It is caused by two overlapping mechanisms: neuromuscular dysfunction during sleep and predisposing anatomic abnormalities. OSA affects individuals across all walks of life, impacting both males and females of all age groups, ethnicities, and weight classes, including those with or without obesity. An estimated 80 million people in the United States and one billion people worldwide suffer from OSA. An individual with OSA can experience hundreds of sleep apnea events in a single night, each one reducing the blood oxygen levels and negatively impacting cellular functions vital to normal health and function. Failure to effectively treat OSA increases the risk of serious long-term health consequences, including cardiovascular, neurocognitive and cardiometabolic damage and heightened mortality. Yet, many patients diagnosed with OSA remain untreated. About Apnimed Apnimed is a privately held late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. We believe the introduction of once-nightly oral drugs has the potential to expand diagnosis and the reach of treatment for people with OSA. We believe that people with OSA would benefit from having multiple drugs with differing mechanisms to more fully address the heterogeneity of OSA's disease pathophysiology. Apnimed envisions a new era where novel oral therapies simplify intervention, expand the reach of diagnosis and treatment, and help more people get the oxygen and restorative sleep needed to thrive. Based in Cambridge, Massachusetts, Apnimed is advancing AD109, designed to improve oxygenation in individuals living with OSA. We believe that AD109 could become the catalyst for a new oral treatment paradigm for OSA that has been historically limited to cumbersome devices or invasive surgeries. AD109 has completed two Phase 3 clinical trials for the treatment of mild, moderate and severe OSA. Learn more at apnimed.com or follow us on X and LinkedIn . Media Contact: media@apnimed.com Investor Contact: ir@apnimed.com View original content to download multimedia: SOURCE Apnimed, Inc.

临床3期

2026-04-07

·集思广JSG咨询

407药讯 Apnimed获得高达1.5亿美元的债务融资艾迪药业：抗艾滋病在研新药ACC085获批临床

正大天晴启动了一项关于TQB2102和TQB2930的新临床试验 2026年4月6日，正大天晴启动了一项关于TQB2102和TQB2930的新临床试验（试验编号：NCT07512583）。TQB2102和TQB2930分别为HER2相关的双特异性抗体和抗体偶联药物。本研究为I b/II期临床试验，旨在评估TQB2930注射液联合TQB2102注射液在HER2表达的晚期实体瘤患者中的安全性和有效性，计划入组患者178例。本次临床试验的试验组药物为TQB2930和TQB2102。海思科启动了PDE3/4抑制剂HSK39004的首个III期临床试验 4月3日，药物临床试验登记与信息公示平台显示，海思科启动了PDE3/4抑制剂HSK39004的首个III期临床试验。该研究是一项随机、多中心、双盲、安慰剂对照临床试验（n=376），旨在评估HSK39004吸入混悬液（每日2次）治疗慢性阻塞性肺病（COPD）患者的有效性和安全性。研究的主要终点是第12周给药后的ΔFEV1AUC0-12h。艾迪药业：抗艾滋病在研新药ACC085获批临床 4月6日晚，艾迪药业（688488）公告其自主研发的1类新药ACC085注射液**获国家药监局临床试验批准，拟用于HIV暴露前预防（PrEP）。该药为**新型HIV-1衣壳功能抑制剂，通过干扰病毒多环节复制起效，临床前显示对多种毒株、耐药株活性优异且具长效潜力。全球HIV防控形势严峻，国内将PrEP列为核心防控策略。ACC085是国内首个进入临床的长效衣壳抑制剂类PrEP药物，与口服长效药ACC077片构成公司HIV预防管线，与现有治疗管线形成“预防-治疗”协同。2025年公司营收7.19亿元（同比+72.13%），亏损大幅收窄。 Apnimed获得高达1.5亿美元的债务融资，与HealthCare Royalty Partners合作，支持计划中的AD109商业发布 4月6日，专注于阻塞性睡眠呼吸暂停（OSA）口服疗法研发的Apnimed公司宣布，与HealthCare Royalty Partners（HCRx）达成最高1.5亿美元的高级担保信贷融资，交易即时拨付5000万美元，剩余两笔各5000万美元将分别在AD109获FDA批准及达成销售里程碑后支付。该融资设有四年只付息期，达标后可延至五年，公司还需支付低个位数比例的合成特许权使用费。此次募资将用于强化财务状况、推进商业化筹备，支持核心产品AD109在美国上市。AD109为全球首创睡前每日一次口服复方药物，可针对OSA神经肌肉病因改善睡眠氧合，已完成两项关键III期临床试验并取得积极结果，公司计划于本季度晚些时候向FDA提交新药申请，有望打破OSA长期依赖器械与手术的传统治疗格局。美国对进口专利药，加征100%的关税近日，特朗普签署文件，依据《1962年贸易扩展法》第232条款，宣布对部分进口专利药及制药成分加征高达100%的关税。该政策将于120天（大型企业）及180天（小型企业）后生效。此举旨在通过极限施压，迫使全球药企将生产线迁回美国并压低药价。对于中国创新药出海的主流模式是“授权出海”（License-out），或将成为避风港，而仿制药企则迎来短暂的“安全窗口期”。 AI皮肤生物科技公司Stratum获200万美元种子轮融资 Stratum Biosciences是一家成立于2024年的生物技术初创公司，总部位于纽约，专注于AI驱动的皮肤生物学发现。该公司利用专有AI平台和超过20万真实皮肤样本库，加速开发新型活性成分和配方，针对护肤和制药领域的皮肤产品。Stratum宣布完成200万美元种子轮融资，由哈佛商学院纽约校友天使投资（Harvard Business School Alumni Angels of Greater New York）和Skin Angels（全球最大皮肤早期投资网络）领投。近杭州本导生物医药科技有限公司（简称“本导基因”）宣布于3月完成数亿元人民币战略融资本轮融资由倚锋资本领投，拱墅国投与宏诚资本跟投。本导基因是一家以体内基因编辑治疗为特色的基因治疗创新药物研发企业，核心竞争力在于其两大自主开发的平台型递送技术：经过临床验证的类病毒载体BD-VLP平台与下一代慢病毒载体BD-Lenti平台。公司运用AI技术优化载体靶向性，持续提升递送系统性能。其中，BD-VLP平台具有瞬时表达、高载量、高靶向性与高编辑效率等特点。核药企业纽瑞特医疗完成10亿元E轮融资近日，成都纽瑞特医疗科技股份有限公司（简称“纽瑞特医疗”）宣布成功完成10亿元人民币的E轮融资。本轮融资由上海科创集团、上海国鑫、南京高科新浚共同领投，弘晖基金等多家机构参与跟投。生物医药行业持续创新，未来可期! 注:本文整理自行业公开信息，仅供参考！

临床3期引进/卖出临床1期财报临床2期

2026-04-07

·Pharmaceutical Technology

Apnimed obtains up to $150m in funds for commercial launch of AD109

AD109 is designed to improve oxygenation during sleep in people with obstructive sleep apnoea. Credit: daniiD / Shutterstock.com. Apnimed has signed a senior secured credit facility of up to $150m with funds managed by HealthCare Royalty Partners (HCRx) to support the planned launch of AD109. The funding will be used for commercial readiness and the potential US launch of the company’s lead product candidate, AD109, pending approval by the US Food and Drug Administration (FDA). The oral pill launch is intended for the treatment of obstructive sleep apnoea (OSA). Apnimed will initially receive $50m at the deal’s closing. An additional $50m tranche is contingent on FDA approval, with a possible third $50m tranche upon reaching a pre-specified sales milestone, subject to customary closing conditions. The agreement includes a four-year interest-only period, which can be extended to five years on Apnimed achieving a specified net sales milestone. The company will also pay a synthetic royalty at a low single-digit percentage of net sales of AD109 and certain other specified revenues, consistent with standard terms and conditions. Apnimed CEO Larry Miller said: “HCR is a highly respected healthcare investor with deep experience in credit financing, and their investment represents an important validation of our investigational product, AD109 and its commercial potential. “This strategic financing provides significant financial flexibility and supports our continued progress toward the potential US commercialisation of AD109, if approved.” HealthCare Royalty Partners chairman and CEO Clarke Futch said: “With its focused regulatory and commercial strategy for AD109, a novel oral therapy designed to address the root causes of OSA, we believe Apnimed is uniquely positioned to meaningfully impact the treatment landscape for patients living with this serious disease.” AD109 is designed to improve oxygenation during sleep by targeting the neuromuscular root cause of upper airway collapse in people with obstructive sleep apnoea. Apnimed previously announced results from the SynAIRgy and LunAIRo Phase III trials of AD109.

临床3期引进/卖出

100 项与 Aroxybutynin/Atomoxetine 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阻塞性睡眠呼吸暂停综合征	临床3期	美国	Apnimed, Inc.	2023-08-28

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05811247 (LunAIRo, PRNewswire)	临床3期	阻塞性睡眠呼吸暂停综合征 --	660	Atomoxetine+Aroxybutynin-AD-109	淵獵願鏇範鹽壓繭糧蓋(襯願蓋範襯鏇網製鏇襯) = 齋淵醖醖夢網憲艱鏇鹽壓繭膚鑰鑰夢糧願蓋獵 (製遞壓顧繭窪繭鬱構範 ) 达到更多	积极	2025-07-23
				placebo	淵獵願鏇範鹽壓繭糧蓋(襯願蓋範襯鏇網製鏇襯) = 網衊壓觸鏇壓憲觸選觸壓繭膚鑰鑰夢糧願蓋獵 (製遞壓顧繭窪繭鬱構範 ) 达到
NCT05813275 (SynAIRgy, PRNewswire) 人工标引	临床3期	阻塞性睡眠呼吸暂停综合征	-	AD109 (aroxybutynin 2.5mg/atomoxetine 75mg)	壓構選鏇鏇壓憲窪窪襯(醖鬱窪鹽鹽鹽壓鹽遞鏇) = 願蓋窪艱壓壓鹹願鏇襯遞鏇鑰窪鬱製艱廠願鬱 (範襯壓廠範醖廠鹹鹹糧 ) 达到更多	积极	2025-05-19
				Placebo	-
MARIPOSA (ERS2023)	N/A	-	-	AD109 75-2.5mg	窪繭範範廠醖鹹襯憲鹽(餘願蓋遞壓夢顧憲窪淵) = 44% had an AHI reduction of more than 50%. 淵範築鬱襯壓築糧醖憲 (構齋夢範鬱遞襯憲廠夢 )	积极	2023-09-09
NCT04580394 (CTgov)	临床2期	阻塞性睡眠呼吸暂停综合征	60	Digit System Substitution Test+AD109 (AD109)	膚醖艱壓鏇糧膚衊壓鹽(鑰遞製廠齋選廠襯憲齋) = 餘艱製鹹顧築蓋選獵選獵膚壓憲簾鬱鹹網鹽鹽 (觸廠願糧鬱觸淵範蓋觸, 築餘製鑰網繭顧簾範醖 ~ 鏇蓋繭築鹹廠鹽網簾製)	-	2023-01-31
				Digit System Substitution Test+Atomoxetine (Atomoxetine)	膚醖艱壓鏇糧膚衊壓鹽(鑰遞製廠齋選廠襯憲齋) = 壓襯鑰製繭鹽獵積鏇夢獵膚壓憲簾鬱鹹網鹽鹽 (觸廠願糧鬱觸淵範蓋觸, 構觸鹹餘鹹遞淵窪鹽衊 ~ 網鹽製鹹鏇壓廠繭範襯)
NCT04631107 (CTgov)	临床2期	阻塞性睡眠呼吸暂停综合征	32	Placebo+AD109 (AD109 dose1 vs Placebo)	餘衊構選繭蓋窪鬱觸範(襯糧艱觸壓網築窪鬱遞) = 壓憲糧製艱鹽鏇餘艱獵繭鹹鹽襯鹽蓋壓網憲鹽 (鹽齋淵遞餘鹽鹹醖遞艱, 窪製餘鬱願顧築鏇廠鏇 ~ 築衊網齋艱夢願窪選繭) 更多	-	2022-12-22
				Placebo+AD109 (AD109 dose2 vs Placebo)	餘衊構選繭蓋窪鬱觸範(襯糧艱觸壓網築窪鬱遞) = 鑰觸糧觸壓選餘簾餘鑰繭鹹鹽襯鹽蓋壓網憲鹽 (鹽齋淵遞餘鹽鹹醖遞艱, 鹽顧鏇製壓餘蓋鏇淵觸 ~ 簾遞構齋憲醖蓋蓋廠網) 更多
WSC2022	临床2期	阻塞性睡眠呼吸暂停综合征	30	Atomoxetine 75 mg + Aroxybutynin 2.5 mg	膚齋壓範膚醖簾艱壓淵(製網遞窪醖顧顧襯簾鬱) = 築餘獵糧獵顧艱膚繭構襯網選範願選膚繭願衊 (鏇糧壓鏇獵窪艱選築範 ) 更多	积极	2022-03-11
				Atomoxetine 37.5 mg + Aroxybutynin 2.5 mg	膚齋壓範膚醖簾艱壓淵(製網遞窪醖顧顧襯簾鬱) = 積簾醖醖蓋選淵構鹽窪襯網選範願選膚繭願衊 (鏇糧壓鏇獵窪艱選築範 ) 更多